Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.

Abstract

Whether non-small cell lung carcinoma (NSCLC) unveiled by immunohistochemistry (IHC) has the same clinical outcome as those typed by morphology is still matter of debate. A total of 145 stage III-IV, consecutive inoperable NSCLC patients treated by chemotherapy (133 cases) or EGFR tyrosine kinase inhibitor (12 cases) and including 100 biopsies, 11 surgical… (More)
DOI: 10.1177/1066896913511527

Topics

Cite this paper

@article{Pelosi2014DoesIA, title={Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.}, author={Giuseppe Pelosi and Eva Regina Haspinger and Manuela Bimbatti and Giorgia Leone and Biagio Paolini and Alessandra Fabbri and Elena Tamborini and Federica Perrone and Adele M Testi and Marina Chiara Garassino and Patrick Maisonneuve and Filippo Guglielmo de Braud and Silvana Pilotti and Ugo Pastorino}, journal={International journal of surgical pathology}, year={2014}, volume={22 2}, pages={136-48} }